Hypertrophic Cardiomyopathy in Review: ESC–HFA 2022 & How to Differentiate HCM From Its Phenocopies
Published: 06 June 2022
-
Views:
3269
-
Likes:
7
-
Views:
3269
-
Likes:
7
Overview
In this two-part hypertrophic cardiomyopathy video series, Dr Ahmad Masri discusses important cardiomyopathy data that has been presented at the ESC–HFA annual congress 2022 and how to differentiate HCM from other conditions that frequently mask, or mimic the diagnosis of HCM.
Supported through an educational grant from Bristol Myers Squibb
Learning Objectives
- Recall the efficacy and safety of existing HCM treatments and summarise results from ongoing trials with experimental treatments
- Differentiate the signs and symptoms of HCM from other conditions that frequently mask, or mimic the disease and in the presence of comorbidities
Target Audience
- Cardiologists
- Heart failure specialists
- Allied healthcare professionals
More from this programme
Part 1
ESC-HFA 2022 (REDWOOD-HCM OLE)
Part 2
How to Differentiate HCM From Its Phenocopies
Faculty Biographies
Ahmad Masri
Dr Ahmad Masri M.D., M.S. trained in Internal Medicine at the Cleveland Clinic.
He specialises in caring for patients with conditions that result in abnormally thickened hearts, such as hypertrophic cardiomyopathy, amyloidosis and Fabry’s disease.